FIT Biotech Oy: FIT Biotech in Sijoitus Invest event on 22 November 2018 – FIT Biotech

Reports and Releases

FIT Biotech Oy: FIT Biotech in Sijoitus Invest event on 22 November 2018

FIT Biotech Oy 
Press release 20.11.2018 at 09:30 EET

FIT Biotech in Sijoitus Invest event on 22 November 2018

FIT Biotech ("Company", FITBIO: FN Finland) is participating in Sijoitus Invest, an annual event for private investors, on Thursday 22 November 2018 at Messukeskus, Helsinki, Finland. Welcome to discuss with us and visit our stand 5 D 19 at 9-18. Come and listen to the presentation about "FIT Biotech as an investment" by Erkki Pekkarinen, CEO of FIT Biotech Oy, on Thursday 22 November at 14.30 on Sijoituslava.

                      Time:                                  Thursday 22 November 2018 at 9-18
                      Location:                             FIT Biotech stand 5 D 19
                                                                 Messukeskus, Helsinki, Finland
                     
                      Presentation:                      FIT Biotech as an investment
                                                                  CEO Erkki Pekkarinen
                                                                 Thursday 22 November at 14.30-14.50
                                                                 Sijoituslava
FIT BIOTECH OY

For further information:
CEO Erkki Pekkarinen
Tel: +358 44 027 0080
E-mail: erkki.pekkarinen@fitbiotech.com

FIT Biotech in brief 

FIT Biotech Oy is a biotechnology company established in 1995 that develops and licenses its patented GTU® (Gene Transport Unit) vector technology for new-generation medical treatments. GTU® is a gene transport technology that meets an important medical challenge in the usability of gene therapy and DNA vaccines. 

FIT Biotech applies its GTU® technology in its development projects, which at the time include gene-based treatments, genetic vaccines and research collaboration. Application areas include cancer (gene therapy) and infectious diseases such as HIV.

FIT Biotech K-shares are listed on the First North Finland market maintained by Nasdaq Helsinki Ltd.

DISTRIBUTION:
Principal media
www.fitbiotech.com

Back to list